Subjects may not have presence of active CNS disease or extramedullary disease.
PHASE II: Confirmed CD+ leukemia recurrence defined as >= .% disease in the marrow or isolated extramedullary disease following allogeneic HCT OR
PHASE II: No prior history of allogeneic HCT (one of the following)\r\n* nd or greater relapse, with or without extramedullary disease (isolated extramedullary disease is eligible)\r\n* st marrow relapse at end of st month of re-induction with marrow having >= .% blast disease, with or without extramedullary disease\r\n* Primary refractory as defined as having M or M marrow after induction\r\n* Subject has indication for HCT but has been deemed ineligible OR
Patients with extramedullary disease only are eligible
Isolated extramedullary disease
Subjects who have received prior radiation therapy for extramedullary disease within  weeks of first dose
Patients with active extramedullary disease.
Patients with extramedullary disease as their sole site of relapsed AML.
Patients with isolated extramedullary disease or with known parenchymal central nervous system (CNS) disease
No evidence of disease-related symptoms and extramedullary disease, including the liver and spleen
Isolated extramedullary leukemia without also meeting bone marrow criteria for leukemia
A histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease.
Participants with extramedullary AML with no evidence of systemic involvement
PHASE II ONLY: Isolated extramedullary relapse
Solitary bone or extramedullary plasmacytoma disease only
No active extramedullary leukemia or known active CNS involvement by malignancy; such disease treated into remission is permitted
Extramedullary leukemia allowed except CNS disease
Extramedullary (CNS) disease;
Patients with known extramedullary leukemia are not eligible
Patients with isolated extramedullary disease or with parenchymal central nervous system (CNS) disease
Patient must have one of the following:\r\n* Recurrent disease with >= % blasts in the bone marrow (M/M bone marrow), with or without extramedullary disease.\r\n* Recurrent disease with an absolute blast count greater than , per microliter in the peripheral blood with or without extramedullary disease
Disease status: \r\n* Phase  (Part A):\r\n** Patients must have either measurable or evaluable disease \r\n* Phase  (Part B):\r\n** Ewing sarcoma or peripheral PNET: patients must have measurable disease\r\n* Phase  (Part C):\r\n** Acute lymphoblastic leukemias (ALL): patients with ALL must have an M marrow with or without extramedullary site of relapse OR an M bone marrow with an extramedullary site of relapse; patients with CNS  status are not eligible for enrollment
Extramedullary disease only.
Isolated extramedullary disease
Patients may have CNS or other sites of extramedullary disease; no cranial irradiation is allowed during the protocol therapy
Isolated extramedullary disease relapse
Active extramedullary disease at any site. (Note: Definitive therapy of known previous sites of extramedullary disease is allowed)
Isolated extramedullary disease (leukemia)
Patient must have relapsed/refractory acute lymphoblastic leukemia (ALL) with ?  blasts in the bone marrow or biopsy confirmed extramedullary disease. Patient may have CNS ,  or  disease. Isolated CNS relapse is not eligible.
Isolated extramedullary disease
Isolated extramedullary disease
Active extramedullary disease
Extramedullary disease in the absence of bone marrow or blood involvement
Extramedullary disease in the absence of any measurable medullary involvement
Patients with known extramedullary leukemia
Extramedullary disease only
Active leukemia in the testes or isolated extramedullary relapse; patients with a history of treated leukemia in testes but no active disease at the time of enrollment are eligible
Isolated extramedullary relapse.